Alumis Inc. (ALMS)
NASDAQ: ALMS · Real-Time Price · USD
25.06
-0.32 (-1.26%)
At close: Mar 20, 2026, 4:00 PM EDT
24.80
-0.26 (-1.04%)
After-hours: Mar 20, 2026, 7:56 PM EDT
Alumis Revenue
In the year 2025, Alumis had annual revenue of $24.05M. Alumis had revenue of $1.93M in the quarter ending December 31, 2025.
Revenue (ttm)
$24.05M
Revenue Growth
n/a
P/S Ratio
132.54
Revenue / Employee
$107,848
Employees
223
Market Cap
3.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 24.05M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionALMS News
- 1 day ago - Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements - GlobeNewsWire
- 3 days ago - Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 19 days ago - Alumis to Present at the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Alumis to Participate in Upcoming February Investor Conferences - GlobeNewsWire
- 2 months ago - Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 2 months ago - Alumis Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise - Seeking Alpha
- 2 months ago - Alumis Announces Proposed Public Offering of Common Stock - GlobeNewsWire